spacer
home > pmps > winter 2002 > the environmental impact of metered dose inhalers
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Environmental Impact of Metered Dose Inhalers

Asthma and chronic obstructive pulmonary disease (COPD) are chronic lung diseases and are among the leading causes of morbidity and mortality in the Western world. Asthma is a reversible narrowing of the airways, combined with a chronic inflammation. For reasons largely unknown, the incidence of asthma is rapidly rising. The number of patients increases annually, and today approximately five per cent of the population of the US and Europe suffer from this disease (1-4).

COPD is a chronic inflammation and destruction of the airways. There is a progressive, non-reversible loss of lung function which will eventually lead to invalidity and death. COPD usually occurs in elderly people, of which most are smokers or former smokers (5).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Cees Winnips MD, Director of Business Development at SkyePharma AG
Cornelis 'Cees' Winnips is educated and trained as a physician and began his career in the pharmaceutical industry in 1989 with Ciba-Geigy in the Netherlands. After a short period in the medical department, he moved to the commercial side and worked as Group Product Manager.

In 1993, he relocated to Austria to head the marketing department of Ciba Austria. In 1995, he moved to the Ciba/Novartis head office in Basel, Switzerland as Manager of Business Development, and subsequently became International Product Manager for the respiratory franchise. In 1998, he joined SkyePharma as Director of Business Development.

spacer
Cees Winnips
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharmaceutical Packaging and Labelling Summit in Zurich; ACG presentation

At next week’s Pharmaceutical Packaging and Labelling Summit in Zurich (18-19 June), Dr. Eugen Hertel from ACG will be speaking on: Challenges for Global Pharma companies to Implement Anti-Counterfeit Strategy for Russian Track & Trace Regulation. This presentation will include details around ‘the fight against counterfeit medicine - there have been and still are worldwide initiatives to make the supply chain and the safety of medicines secure. After large markets such as the USA and Europe passed their laws and regulations for the pharmaceutical manufacturing companies and established the IT infrastructure, Russia is now next on the move.
More info >>

White Papers

Changing Structural Landscape for Comparator Drug Supply

ADAllen Pharma

TransCelerate Biopharma is focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. In 2013, they announced its Clinical Trial Comparator Network initiative to show a mutual commitment to offer secure and rapid supply of comparator drug products. The aim of this article is to unpack the section on 'Comparator Drugs' and analyse the rationale for attempting to achieve their objectives.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement